Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5037-5042

  Gamez, Idoia ^a   Ryan, Robert P ^a   Keir, Stephen T ^b  

^a Celtic Pharmaceutical Development Services America Inc   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Avastin ; Bevacizumab; Brain tumor model; Corticorelin acetate; Xerecept

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CORTICORELIN ACETIC ACID; CORTICOTROPIN RELEASING FACTOR; UNCLASSIFIED DRUG; XERECEPT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MEDULLOBLASTOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ACETATES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751494651     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stummer W: Mechanisms of tumor-related brain edema. Neurosurg Focus 22: E8, 2007.
2. Lee SW, Kim WJ, Park JA, Choi YK, Kwon YW and Kim KW: Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 29: 265-275, 2006. (Pubitemid 43685278)
3. Tjuvajev J, Uehara H, Desai R, Beattie B, Matei I, Zhou Y, Kreek MJ, Koutcher J and Blasberg R: Corticotropin-releasing factor decreases vasogenic edema. Cancer Res 56: 1352-1360, 1996.
4. Kaal EC and Vecht CJ: The management of brain edema in brain tumors. Curr Opin Oncol 16: 593-600, 2004.
5. Grammatopoulos DK and Chrousos GP: Functional characteristics of CRH receptors and potential clinical applications of CRHreceptor antagonists. Trends Endocrinol Metab 13: 436-444,2002.
6. Hillhouse EW and Grammatopoulos OK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260-286, 2006.
7. Reubi JC, Waser W, Vale W and Rivier J: Expression of CRFl and CRF2 receptors in human cancers. J Clin Endocrinol Metab 55:3312-3320,2003.
8. Bale TL, Giordano FJ and Vale WW: A new role for corticotrophin-releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med 13: 68-71, 2003.
9. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G and Li S: Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26: 359-368, 2008.
10. Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP and Wong ET: A placebocontrolled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol 27: abstr 2078, 2009.
11. Mechtler L, Wong ET, Hormigo A, Pannullo S, Hines V, Milsted R, O'Connor PO, Ryan RP and Recht L: A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. J Clin Oncol 27: abstr 2079, 2009.
12. Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted R, O'Connor PC, Ryan RP and Recht L: A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema. J Clin Oncol 27: abstr 2080, 2009.
13. Moliterno JA, Henry E and Pannullo SC: Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin Investig Drugs 18: 1413-1419, 2009.
14. Ryan R, Moroz M, Berestein T, Evans-Freke S, Gamez I, Hines V and Blasberg R: Corticorelin acetate exhibits preclinical antitumor activity against the human glioma U87 xenograft. Proc Amer Assoc Cane Res abstr 2326, 2009.
15. Gamez I, Ryan RP, Reid LD, Routt SM and Hollister BA: Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models. Cancer Chemother Pharmacol, Online First™ , 2 September 2010.
16. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr., Jacobsen, PF, Muhlbaier LH and Bigner DD: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189-4195, 1988.
17. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M and Sausville EA: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431, 2001.
18. Kleinbaum DG and Klein M: Survival Analysis: A Self-Learning Text, 2nd Edition. New York: Spring. Statistics for Biology and Health, 2005.
19. Gehan EA: A generalized Wilcoxon test for comparing arbitrary dingly-censored samples. Biometrika 52: 203-223, 1965.
20. Velaperthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hulburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmerman K, Trainor G and Vyas D: Discovery and Evaluation of 4-(2-(4-chlor-1H-pyrazol-1-y1) ethylamino)-3-(6(1-(3-fluoropropyl) piperidin-4-y1)-4-methyl-1/7-benzo (d) imidazol-2-yl pyridin-2 (1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth Factor-I receptor kinase with broad-spectrum in vivo antitumor activity. J. Med. Chem 51: 5897-5900, 2008. Note: the referenced formula of interest is provided within supplemental material available on line via the Internet at: http://pubs.acs.org
21. Altman DG: Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
22. Hao Z, Huang Y, Clernan J, Jovin IS, Vale WW, Bale TL and Giordano FJ: Urocortin 2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci 105: 3939-3944, 2008.
23. Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, Matei C, Koutcher J, Kreek MJ and Blasberg R: Antineoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 12: 1-10, 1998.